共 47 条
- [21] Clinical Impact of Solifenacin on Generic and Symptom-Specific Quality of Life for Females with Overactive Bladder: Using the Overactive Bladder Symptom Score and Rand Medical Outcomes Study 36-Item Health SurveyLUTS-LOWER URINARY TRACT SYMPTOMS, 2013, 5 (01) : 5 - 10Yano, MasashiSuzuki, HiroyoshiKamiya, NaotoKato, TomonoriNomura, KazushiKuramochi, HiroakiOhta, ShoMikami, KazuoNakatsu, HiroomiOkano, TatsuyaOnishi, TetsuroIchikawa, Tomohiko
- [22] Detecting change in psychiatric functioning in clinical trials for cocaine use disorder: sensitivity of the Addiction Severity Index and Brief Symptom InventoryDRUG AND ALCOHOL DEPENDENCE, 2021, 228Kiluk, Brian D.Roos, Corey R.Aslan, MihaelaGueorguieva, RalitzaNich, CharlaBabuscio, Theresa A.Carroll, Kathleen M.
- [23] Identifying the concepts contained in outcome measures of clinical trials on stroke using the international classification of functioning, disability and health as a referenceJOURNAL OF REHABILITATION MEDICINE, 2004, 36 : 56 - 62Geyh, SKurt, TBrockow, TCieza, AEwert, TOmar, ZResch, KL
- [24] Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: Using international prostate symptom score and Rand Medical Outcomes Study 36-item Health SurveyINTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (09) : 1202 - 1206Suzuki, HiroyoshiYano, MasashiAwa, YusukeNakatsu, HiroomiEgoshi, Ken-IchiMikami, KazuoOta, ShoOkano, TatsuyaHamano, SatoruOhki, TakemasaFuruya, YuzoIchikawa, Tomohiko
- [25] Domain-Specific Outcome Measures in Clinical Trials of Therapies Promoting Stroke Recovery: A Suggested BlueprintSTROKE, 2023, 54 (03) : E86 - E90Cramer, Steven C.Lin, David J.Finklestein, Seth P.
- [26] The case for modality-specific outcome measures in clinical trials of stroke recovery-promoting agentsSTROKE, 2007, 38 (04) : 1393 - 1395Cramer, Steven C.Koroshetz, Walter J.Finklestein, Seth P.
- [27] Identifying the concepts contained in outcome measures of clinical trials on breast cancer using the international classification of functioning, disability and health as a referenceJOURNAL OF REHABILITATION MEDICINE, 2004, 36 : 43 - 48Brockow, TDuddeck, KGeyh, SSchwarzkopf, SRWeigl, MFranke, TBrach, M
- [28] Identifying the concepts contained in outcome measures of clinical trials on depressive disorders using the international classification of functioning, disability and health as a referenceJOURNAL OF REHABILITATION MEDICINE, 2004, 36 : 49 - 55Brockow, TTWohlfahrt, KHillert, AGeyh, SWeigl, MFranke, TResch, KLCieza, A
- [29] USING REPEATED-MEASURES OF SYMPTOM SCORE, UROFLOWMETRY AND PROSTATE-SPECIFIC ANTIGEN IN THE CLINICAL MANAGEMENT OF PROSTATE DISEASEJOURNAL OF UROLOGY, 1995, 153 (01): : 99 - 103BARRY, MJGIRMAN, CJOLEARY, MPWALKERCORKERY, ESBINKOWITZ, BSCOCKETT, ATKGUESS, HAHOLTGREWE, HLMCCONNELL, JDSIHELNIK, SAMCLEOD, MWINFIELD, HNWILLIAMS, R
- [30] Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trialsLANCET PSYCHIATRY, 2019, 6 (06): : 528 - 537Wong, Ian C. K.Banaschewski, TobiasBuitelaar, JanCortese, SamueleDoepfner, ManfredSimonoff, EmilyCoghill, DavidAsherson, PhilSantosh, ParamalaSmirnoff, EmilySonuga-Barke, Edmund J.Taylor, EricDaley, DavidHollis, ChrisFerrin, MaiteDittmann, Ralf W.Holtmann, MartinRothenberger, AribertBrandeis, DanielSteinhausen, Hans-ChristophDanckaerts, Marinavan der Oord, SaskiaKonofal, EricLecendreux, MichelSoutullo, CesarStringaris, ArgyrisZuddas, Alessandro